Ilginatinib

CAS : 1239358-86-1

Ref. 3D-PZB35886

Informations sur le produit

• Nom: Ilginatinib
• Synonymes: 2,6-Pyridinediamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-, N2-[(1S)-1-(4-Fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-2-pyrazinyl-2,6-pyridinediamine, (S)-N-[1-(4-Fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N′-(pyrazin-2-yl)pyridine-2,6-diamine, NS 018

Description

Ilginatinib is a cell-factor inhibitor that has been identified as a potential therapeutic agent for the treatment of cancers. Ilginatinib inhibits Jak2V617F, which is an oncogenic mutation in the Jak2 gene. This mutation leads to uncontrolled growth and survival of hematopoietic cells, which are cells that produce blood cells. Ilginatinib has been shown to inhibit colony-stimulating factor (CSF), which is an inflammatory cytokine that can lead to tumor progression. The molecular modeling study indicated that ilginatinib may bind with hydrogen bonds to the active site of Jak2V617F and thereby inhibit its activity. It also prevents activation of jak2 v617f by inhibiting epidermal growth factor receptor, which is a cell surface protein. Ilginatinib also inhibits the synthesis of hematopoietic growth factors such as stem cell factor and erythropoietin, leading to decreased proliferation in these

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 389.43 g/mol
• Formule: C₂₁H₂₀FN₇
• Degré de pureté: Min. 95%